Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute Clinical Trial

Official title:

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05984199
• Other study ID #: VBP301
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 11, 2023
• Est. completion date: November 2026

Study information

• Verified date: May 2024
• Source: Vor Biopharma
• Contact: Jennifer Whangbo, MD, PhD
• Phone: 617-655-6580
• Email: clinicaltrials[@]vorbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).

Description:

CD33 is a preferential target for AML CAR T cell therapy due to its surface expression on the majority (>80%) of AML blasts and due to the extensive prior clinical experience demonstrating safety and efficacy of targeting CD33 with Mylotarg (gemtuzumab ozogamicin). VCAR33 is being developed as a potential new treatment for patients with relapsed/refractory (R/R) AML after alloHCT. In this Phase 1/2 trial, the safety and efficacy of lentiviral-transduced CD33-directed CAR T cells (VCAR33) generated from the patient's prior allogeneic stem cell donor will be tested. It is hypothesized that CAR T cell production from healthy donors will not only eliminate delays in production due to lymphopenia but also reduce concerns for suboptimal T cell function from exposure to systemic immunosuppression or chemotherapeutic agents. Approximately 24 eligible patients with R/R AML after alloHCT will be enrolled in one of two separate arms based on disease burden (morphologic disease versus measurable residual disease (MRD ) positive). The maximum tolerated dose of VCAR33 will be determined using a 3+3 trial design within each arm. Dose escalation can only occur after a minimum of 3 patients have completed the dose-limiting toxicity (DLT) observation period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: November 2026
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients aged =18 years

2. Patients must have CD33+ AML in relapse or refractory after alloHCT

3. Patients must be a recipient of an 8/8 (A, B, C, DRB1) HLA-matched related or unrelated donor alloHCT. Patients previously transplanted with VOR33 in the VBP101 study who have R/R AML may also be considered.

4. Disease status at the time of enrollment:

1. Arm A/Morphologic disease: Defined as = 5% blasts (bone marrow) post-HCT

2. Arm B/MRD positive: < 5% blasts (bone marrow) with minimal residual disease of at least 0.1% CD33+ leukemia cells by flow cytometry

5. Performance status: ECOG 0 or 1

6. Patient must have adequate organ function as defined by:

1. Cardiac: Left ventricular ejection fraction (LVEF) = 45% or fractional shortening = 28%

2. Pulmonary: Baseline oxygen saturation > 92% on room air at rest

3. Hepatic: Total bilirubin < 3x institutional upper limit of normal (ULN) (except in case of patients with documented Gilbert's disease < 5x ULN) and aspartate aminotransferase (AST/SGOT)/alanine aminotransferase (ALT/SGPT) < 5x institutional ULN

4. Renal: Serum creatinine must be = 1.2x institutional ULN or creatinine clearance = 60 mL/min for patients with creatinine levels above institutional normal

7. Original alloHCT donor is available and willing to undergo apheresis

Exclusion Criteria:

1. Patients who have undergone more than one alloHCT

2. Patients who have undergone alloHCT with a mismatched unrelated donor, haploidentical donor, or with umbilical cord blood as the stem cell source

3. Patients who will be less than 100 days post-alloHCT at the time of VCAR33 infusion.

4. Patients with any history of Grade III or IV acute GVHD or severe chronic GVHD unless approved by the Sponsor Medical Monitor

5. Patients with evidence of ongoing active acute or chronic GVHD and are taking systemic immunosuppressive agents (> 10 mg daily of prednisone equivalent or other GVHD-directed treatment, including extracorporeal photopheresis). Patients with Grade 1 acute GVHD limited to the skin or mild chronic GVHD limited to the eyes, mouth, or skin controlled with only topical therapy are eligible.

6. Patients with active CNS disease. A lumbar puncture is not required to exclude CNS disease in the absence of clinical signs or symptoms suggesting CNS disease.

7. Patients with the following prior therapy:

1. DLI within 28 days prior to enrollment

2. Prior treatment with any CAR T cell therapy product

8. Patients with active or uncontrolled viral, bacterial, or fungal infection

9. Patients with a history of a human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection

10. Patients with a history of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, or breast) unless disease free for at least 3 years after the last definitive therapy

11. Female patients of childbearing potential who are pregnant or breastfeeding

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Biological:
• VCAR33
Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy

Locations

Country	Name	City	State
United States	University of Michigan Health	Ann Arbor	Michigan
United States	National Institutes of Health, Clinical Center	Bethesda	Maryland
United States	University Hospitals Seidman Cancer Center	Cleveland	Ohio
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	The University of Kansas Cancer Center	Fairway	Kansas
United States	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey
United States	University of California San Diego Moores Cancer Center	La Jolla	California
United States	Miami Cancer Institute	Miami	Florida
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Washington University School of Medicine Siteman Cancer Center	Saint Louis	Missouri
United States	University of Utah Huntsman Cancer Institute	Salt Lake City	Utah
United States	Stanford Cancer Institute	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Vor Biopharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicities		Day 28
Secondary	Incidence of GVHD related to VCAR33		Up to 24 months
Secondary	Percentage of patients who achieve response		Up to 24 months
Secondary	Overall survival post-VCAR33 infusion		Up to 24 months
Secondary	Progression-free survival post-VCAR33 infusion		Up to 24 months